CDK1 and breast cancer: To investigate the clinical significance of CDK1‐mediated phosphorylation of TFCP2L1 (p‐TFCP2L1) in BC progression, we used an in‐house polyclonal antibody specific for p‐TFCP2L1 (Appendix Fig S2).